Ownership and insider activity for Organogenesis Holdings Inc. (ORGO): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that specializes in creating, producing, and marketing innovative therapies for advanced wound management, as well as surgical and sports medicine applications. Within its advanced wound care portfolio, Organogenesis offers several distinct products.
Price
| Price | $1.39 |
| Market Cap | $179M |
| Exchange | NASDAQ |
| Country | US |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.0M | $125886 | $21.3M | $60.2M | $84.4M | $113.9M | $102.5M | $104.3M | $135.6M | $93.7M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 0 | 0 | $34.1M | $39.4M | $56.8M | $82.5M | $89.5M | $82.0M | $109.9M | $217.5M |
| Inventory | 0 | 0 | $13.3M | $22.9M | $27.8M | $25.0M | $24.8M | $28.3M | $26.2M | $29.6M |
| Total Current Assets | $1.4M | $294439 | $71.1M | $125.6M | $174.3M | $227.0M | $222.6M | $225.0M | $285.9M | $362.2M |
| Property, Plant & Equipment | 0 | 0 | $39.6M | $47.2M | $55.8M | $128.3M | $145.7M | $156.3M | $126.2M | $159.5M |
| Goodwill | 0 | 0 | $25.5M | $25.5M | $28.8M | $28.8M | $28.8M | $28.8M | $28.8M | $28.8M |
| Intangible Assets | 0 | 0 | $26.1M | $20.8M | $30.6M | $25.7M | $20.8M | $15.9M | $12.5M | $9.1M |
| Total Assets | $311.4M | $312.8M | $163.7M | $220.7M | $290.2M | $443.3M | $449.4M | $460.0M | $497.9M | $598.7M |
| Accounts Payable | 0 | $19.1M | $19.2M | $28.4M | $23.4M | $29.3M | $32.3M | $30.7M | $28.9M | $31.9M |
| Short-term Debt | 0 | $100000 | $2.5M | 0 | $16.7M | $2.7M | $4.5M | $5.5M | 0 | $18.6M |
| Total Current Liabilities | $478360 | $3.9M | $66.4M | $59.9M | $68.2M | $82.7M | $75.0M | $80.5M | $77.5M | $100.1M |
| Long-term Debt | 0 | 0 | $39.1M | $83.1M | $53.0M | $70.8M | $66.2M | $60.7M | 0 | $50.7M |
| Total Liabilities | $11.3M | $14.8M | $116.6M | $165.1M | $148.4M | $201.9M | $183.7M | $181.4M | $112.6M | $164.8M |
| Retained Earnings | -$233860 | -$2.3M | -$130.2M | -$171.0M | -$155.0M | -$60.8M | -$45.3M | -$41.0M | -$40.1M | -$3.1M |
| Total Equity | $300.1M | $298.0M | $47.0M | $55.6M | $141.8M | $241.3M | $265.7M | $278.7M | $385.3M | $433.9M |
| Total Debt | 0 | $17.9M | $59.3M | $100.6M | $84.8M | $132.3M | $123.8M | $119.4M | $43.3M | $132.8M |
| Net Debt | -$1.0M | $17.7M | $38.0M | $40.4M | $377000 | $18.4M | $21.3M | $15.0M | -$92.3M | $39.2M |
| Working Capital | $957551 | -$3.6M | $4.7M | $65.7M | $106.1M | $144.3M | $147.6M | $144.5M | $208.5M | $262.1M |
Financial Health
| Debt / Equity | 0.23 |
| Current Ratio | 3.52 |
| Piotroski F-Score | 4 |
| Altman Z-Score | 4.16 |
Profitability
| Return on Equity | -24.23% |
| Return on Invested Capital | -8.12% |
| Return on Assets | -22.20% |
| Gross Margin | 67.59% |
| Operating Margin | -6.38% |
| Net Margin | -19.76% |
Related companies: ANGO · BCYC · CMPX · EBS · EOLS · ESPR · MNPR
Explore sector: Healthcare · Drug Manufacturers - Specialty & Generic
More sections of ORGO: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks